ACOG's updated menopause guidance includes five nonmedication approaches for hot flashes, sleep and mood. Learn how to interpret the recommendations.
ACOG published Clinical Practice Guideline No. 13 on October 15, 2026. Titled “Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms,” it addresses hormonal and nonhormonal options for those concerns. The update includes recommendations for approaches such as cognitive behavioral therapy and acupuncture alongside medication.
For readers following menopause care, the development is a wider range of approaches to discuss rather than a single new treatment. ACOG describes this as its most comprehensive menopause-management guidance to date. Understanding which symptoms it addresses is the starting point for interpreting the news.
This is a clinical practice guideline rather than a new trial following one group of participants. Its scope covers menopause-related hot flashes and night sweats as well as sleep and mood symptoms. The relevant framework is a set of care recommendations, not a single experiment with one participant count or follow-up period.
ACOG says the guidance includes more detail on hormone therapy and nonhormonal options. It also adds recommendations for nonpharmacologic interventions, the clinical term for approaches that do not involve medication. These categories sit within the same guideline rather than being presented as separate systems of care.
That distinction helps explain the update's purpose. The question is not simply whether menopause care should involve hormones. The guidance presents several kinds of care that clinicians and patients can discuss in relation to the symptoms being addressed.
ACOG highlights five nonpharmacologic approaches:
ACOG says these approaches can be used alone. However, it generally recommends considering them as options in combination with hormonal or other medications. That wording leaves room for different care plans without requiring every person to use medication or every nonmedication approach to be paired with it.
The practical change is that a discussion about symptom management can include these approaches within the same conversation as medication. It is not framed as a contest between two opposing choices. A care plan may draw from more than one category.
Nonhormonal medication is a separate category from nonmedication care. ACOG's announcement identifies SSRIs and SNRIs alongside neurokinin receptor antagonists such as fezolinetant and elinzanetant. These appear alongside hormone therapy and nonpharmacologic approaches in the updated guidance.
When reading about “nonhormonal options,” it therefore helps to ask what the phrase means. It may refer to medicines or to an intervention that does not use medicine. Keeping those categories distinct makes the recommendations easier to understand and gives a clinical conversation a clearer starting point.
Contemporary OB/GYN reports that the recommendations for the five nonpharmacologic approaches are conditional. It describes low-to-moderate-quality evidence for CBT, mindfulness and exercise. For clinical hypnosis and acupuncture, it reports low-quality evidence.
A conditional recommendation supports considering an option in context rather than promising benefit for every person. The different evidence ratings also mean the five approaches should not be presented as equally well established. Inclusion in a guideline is not an instruction to replace an existing treatment.
For a sexual-wellness audience, the boundary around outcomes is especially important. ACOG's announcement does not establish these approaches as treatments for low desire, arousal concerns, vaginal dryness or pain during sex. Managing the symptoms covered by this guideline may matter to broader wellbeing, but that is different from demonstrating an improvement in sexual function or intimacy.
ACOG says it is developing separate guidance on genitourinary syndrome of menopause, planned for 2027. Questions about sexual symptoms belong in their own clinical discussion rather than being answered by extending these recommendations beyond their stated scope.
The expanded options do not remove hormone therapy from the discussion. ACOG says its updated guidance includes a more detailed review of hormone-therapy evidence as well as nonhormonal choices. The update is best understood as a broader framework for care rather than a declaration that one category has replaced another.
ACOG coauthor Robert P. Kauffman said hormone therapy can be a good option but may not be appropriate or helpful for every person. He described the range of hormonal and nonhormonal choices as a way to support individualized care. That places the new recommendations alongside established treatment discussions rather than outside them.
Other menopause guidance also illustrates why scope matters. A separate Department of Defense menopause guideline addresses genitourinary syndrome and sexual dysfunction alongside other menopause-related health areas. Those recommendations belong to that separate guideline and should not be attributed to ACOG's update.
For readers considering sexual comfort within wider menopause care, the distinction is useful. “Menopause guidance” is not one interchangeable document. Different guidelines may address different symptoms and clinical questions.
The update also distinguishes evidence-based nonmedication care from assumptions about products described as natural. ACOG says evidence does not support the safety or efficacy of phytoestrogens or herbal supplements for vasomotor or other menopausal symptoms. Including acupuncture or mindfulness in the guidance is not a general endorsement of everything marketed without a prescription.
Taken together, these points place the announcement within an ongoing review of menopause care. The meaningful comparison is between specific recommendations for specific symptoms, not between a supposedly old approach and an entirely new philosophy of treatment.
The useful starting point is the symptom a person wants addressed rather than the longest possible list of treatments. A discussion about night sweats may have a different goal from a discussion about mood. Naming the main concern helps keep the conversation connected to the relevant part of the guidance.
ACOG says hormone-therapy decisions should consider symptoms and age along with medical history and baseline risks. It also places the person's goals and priorities within shared decision-making. In plain language, the evidence informs the conversation while individual circumstances shape the decision.
Readers could use questions such as these to discuss the update with a qualified clinician:
These questions separate two issues: the choices included in a guideline and the choices suited to a particular person. A broader menu does not make the decision less personal. It makes clarity about the goal more important.
It can also be useful to clarify the language used during an appointment. “Nonhormonal” and “nonmedication” describe different categories. Asking which one is being discussed is a straightforward way to understand the proposed direction without assuming that a label explains the entire care plan.
For readers weighing hormone-related questions, understanding how treatment timing fits personal context offers a related perspective. The point is not to select an option from a headline. It is to understand what information belongs in an individualized discussion.
There is room to name concerns about confidence or intimacy in that conversation too. Those concerns do not have to disappear simply because an appointment began with hot flashes or sleep. They can be stated as questions about wellbeing without being turned into a self-diagnosis.
The guideline supplies a framework for discussing care rather than a personal treatment plan. Decisions about which approach to use belong with a qualified clinician who can consider the person's circumstances and priorities.
Questions about sexual wellbeing deserve clear language and a place in the conversation.
Matching a menopause recommendation to the symptom it addresses is a key reading decision, and Sexential adds evidence-aware educational context. For adults aged 35 to 65 who are uncertain about influences on sexual function, its coverage connects biology with everyday circumstances to support clearer understanding without providing personalised medical advice.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
Women reported energy, mood and sexual-interest gains during testosterone care. See the study’s limits and how its findings compare with current guidance.
Different desire levels need context, not blame. Understand possible influences, discuss changing needs and recognize when professional input may help.
Compare spontaneous and responsive desire in midlife, with evidence, relationship questions and a clear distinction between openness and obligation.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
